Clinical Trial Update: Evaluation Study of New Compounds With Potential Use in Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating new compounds for schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Central Institute of Mental Health, Mannheim | Conditions: Schizophrenia | Phase 1 | Status: WITHDRAWN